FAW Teams up with RoboSense on The World’s First Automotive-grade Solid-state Smart LiDAR Sensor for Serial Production
27.9.2019 18:00:00 EEST | Business Wire | Press release
RoboSense, the pioneering Smart LiDAR Sensor provider, announced a partnership with FAW ("First Automobile Works"), the world's leading automotive OEM (Original Equipment Manufacturer), and showcased the milestone achievement of last year’s cooperation: the first batch of world’s first solid-state Smart LiDAR Sensor RS-LiDAR-M1 on September 25. The deal is to include RS-LiDAR-M1 as core component into FAW's proprietary next-generation autonomous driving system development, therefore accelerating the serial production of the world's first automotive-grade solid-state MEMS-based Smart LiDAR Sensor, in order to promote Level 3 vehicle autonomy and above.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190927005229/en/
FAW Teams up with RoboSense on The World’s First Automotive-grade Solid-state Smart LiDAR Sensor for Serial Production (Photo: Business Wire)
The final commercialized version of RS-LiDAR-M1 is the world’s first and only all-in-one unit MEMS-based Smart LiDAR Sensor for self-driving passenger vehicles with its own embedded AI algorithm technologies and SoC (System of Chip). It transforms traditional LiDAR systems (also known as solely data collectors), to full data analysis and comprehension systems. The RS-LiDAR-M1 not only collects and interprets high definition 3D point cloud data, but its built-in AI algorithm and SoC also process road data in real-time, while at the same time synchronizing outputs of high-precision localization, obstacle detection, tracking and classification, road curbs and driving areas detection.
Unlike RoboSense Smart LiDAR Sensor, when mechanical LiDAR is used on a vehicle, a computer-sized ECU must also be used to operate the algorithms. Compared with ECUs, the RoboSense dedicated SoC built into the Smart LiDAR Sensor not only withstands strong bumps and jolts in the vehicle, but is also small and light-weight. The RoboSense Smart LiDAR Sensor's built-in SoC can largely reduce more power consumption while improving performance compared to automotive ECUs, saving much more passenger space at the same time.
The RS-LiDAR-M1 is cleanly designed in a streamlined body that allows it to be easily embedded onto any part of the vehicle for the complete aesthetics of automobile.
Serial produced RoboSense Smart LiDAR Sensor costs only hundreds of dollars each, based on its deployment of revolutionary MEMS micro-mirror scanning structure and simplified manufacturing and streamlines production, while maintaining high product quality and reliability to meet exacting OEM requirements.
Fengjun Li, Director of Intelligent Connected Vehicle Development Institute, FAW, said, "China is standing at the front of the world's autonomous driving development. Our cooperation with RoboSense demonstrates our confidence in Smart LiDAR Sensor for Level 3 vehicle autonomy and above, and accelerates the commercialized development of our proprietary next-generation autonomous driving system”.
"The RS-LiDAR-M1 is a revolutionary product developed upon more than ten years of research development accumulated by the RoboSense team. We believe the partnership will enhance the serial production ability of automotive-grade Smart LiDAR Sensor for autonomous driving,” said Steven Qiu ChuanXin, RoboSense Founder and CEO.
At the signing ceremony, the closest to commercialized version of Smart LiDAR Sensor RS-LiDAR-M1 delivered by RoboSense will be used for FAW's automotive-grade testing and self-driving passenger cars research development. The current version has greatly improved performance while reducing the size to only the half of the former demo showcased on CES 2019, which can be easily integrated into any part of the vehicle body. More details of the latest version will be coming soon.
About RoboSense:
Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the first and only MEMS-based Smart LiDAR Sensor for autonomous driving.
For more information about RoboSense please visit: https://www.robosense.ai/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190927005229/en/
Contact information
Media:
Cassie Gong, PR Manager
sqgong@robosense.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom